Genetic testing for pathogenic variants in breast cancer gene 1/2 (BRCA1/2) can identify individuals at increased cancer risk (specifically breast and ovarian), provide opportunities for risk management (i.e., cancer surveillance) and cancer prevention (i.e., risk-reducing surgery or medication), and benefit blood relatives via cascade carrier screening (The National Comprehensive Cancer Network, 2023). The gene discussed is BRCA1; the disease is breast carcinoma.